Reduction of α-dystroglycan expression is correlated with poor prognosis in glioma

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11621-11629

  Zhang, Xin ^a   Dong, Xiang Hui ^a   Ma, Yue ^a   Li, Lan Feng ^a   Wu, He ^a   Zhou, Min ^a   Gu, Yun He ^a   Li, Guo Zhong ^a   Wang, De Sheng ^a   Zhang, Xiao Feng ^a   Mou, Jing ^a   Qi, Ji Ping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Dystroglycan; Glioma; Prognostic marker; Survival analysis

Indexed keywords

DAG1 PROTEIN, HUMAN; DYSTROGLYCAN; GELATINASE B; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; BRAIN TUMOR; CANCER GRADING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MALE; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; BRAIN NEOPLASMS; DYSTROGLYCANS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84927785771     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2418-7     Document Type: Article

References (38)

1. Winder SJ. The complexities of dystroglycan. Trends Biochem Sci. 2001;26:118–24.
2. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci. 2006;119:199–207.
3. Waite A, Brown SC, Blake DJ. The dystrophin-glycoprotein complex in brain development and disease. Trends Neurosci. 2012;35:487–96.
4. Sgambato A, Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol. 2005;205:163–9.
5. Brennan PA, Jing J, Ethunandan M, Gorecki D. Dystroglycan complex in cancer. Eur J Surg Oncol. 2004;30:589–92.
6. Moore SA, Saito F, Chen J, Michele DE, Henry MD, Messing A, et al. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature. 2002;418:422–5.
7. Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, et al. Anomalous dystroglycan in carcinoma cell lines. FEBS Lett. 2000;484:194–8.
8. Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol. 2003;162:849–60.
9. Sgambato A, Camerini A, Amoroso D, Genovese G, De Luca F, Cecchi M, et al. Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biol Ther. 2007;6:1840–6.
10. Moon YW, Rha SY, Zhang X, Jeung HC, Yang WI, Kwon O, et al. Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. J Surg Oncol. 2009;100:459–65.
11. Sgambato A, Camerini A, Genovese G, De Luca F, Viacava P, Migaldi M, et al. Loss of nuclear p27(kip1) and alpha-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. Cancer Sci. 2010;101:2080–6.
12. Shimojo H, Kobayashi M, Kamigaito T, Shimojo Y, Fukuda M, Nakayama J. Reduced glycosylation of alpha-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer. Prostate. 2011;71:1151–7.
13. Bao X, Fukuda M. A tumor suppressor function of laminin-binding alpha-dystroglycan. Methods Enzymol. 2010;479:387–96.
14. Satz JS, Ostendorf AP, Hou S, Turner A, Kusano H, Lee JC, et al. Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J Neurosci. 2010;30:14560–72.
15. Myshrall TD, Moore SA, Ostendorf AP, Satz JS, Kowalczyk T, Nguyen H, et al. Dystroglycan on radial glia end feet is required for pial basement membrane integrity and columnar organization of the developing cerebral cortex. J Neuropathol Exp Neurol. 2012;71:1047–63.
16. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med. 2012;33:579–89.
17. Gritsenko PG, Ilina O, Friedl P. Interstitial guidance of cancer invasion. J Pathol. 2012;226:185–99.
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
19. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467–73.
20. Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013;113:259–66.
21. Siangprasertkij C, Navalitloha Y. A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival. J Med Assoc Thai. 2008;91:491–6.
22. Sun ZF, Wang L, Gu F, Fu L, Li WL, Ma YJ. Expression of Notch1, MMP-2 and MMP-9 and their significance in glioma patients. Zhonghua Zhong Liu Za Zhi. 2012;34:26–30.
23. Zhao J, Li G, Zhao Z, Wang J, Gao G, He S. Matrix metalloproteinase-9 expression is increased in astrocytic glioma and associated with prognosis of patients. Jpn J Clin Oncol. 2012;42:1060–5.
24. Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, et al. Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol Ther. 2006;5:441–8.
25. Noell S, Wolburg-Buchholz K, Mack AF, Ritz R, Tatagiba M, Beschorner R, et al. Dynamics of expression patterns of aqp4, dystroglycan, agrin and matrix metalloproteinases in human glioblastoma. Cell Tissue Res. 2012;347:429–41.
26. de Bernabe DB, Inamori K, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, et al. Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of large. J Biol Chem. 2009;284:11279–84.
27. Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta. 1838;2014:635–42.
28. Chand D, Song L, deLannoy L, Barsyte-Lovejoy D, Ackloo S, Boutros PC, et al. C-terminal region of teneurin-1 co-localizes with dystroglycan and modulates cytoskeletal organization through an extracellular signal-regulated kinase-dependent stathmin- and filamin a-mediated mechanism in hippocampal cells. Neuroscience. 2012;219:255–70.
29. Zhou YW, Munoz J, Jiang D, Jarrett HW. Laminin-alpha1 LG4-5 domain binding to dystroglycan mediates muscle cell survival, growth, and the AP-1 and NF-kappaB transcription factors but also has adverse effects. Am J Physiol Cell Physiol. 2012;302:C902–14.
30. Budinger GR, Urich D, DeBiase PJ, Chiarella SE, Burgess ZO, Baker CM, et al. Stretch-induced activation of AMP kinase in the lung requires dystroglycan. Am J Respir Cell Mol Biol. 2008;39:666–72.
31. Zhou Y, Jiang D, Thomason DB, Jarrett HW. Laminin-induced activation of Rac1 and JNKp46 is initiated by Src family kinases and mimics the effects of skeletal muscle contraction. Biochemistry. 2007;46:14907–16.
32. Spence HJ, Dhillon AS, James M, Winder SJ. Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 2004;5:484–9.
33. Masaki T, Matsumura K, Saito F, Yamada H, Higuchi S, Kamakura K, et al. Association of dystroglycan and laminin-2 coexpression with myelinogenesis in peripheral nerves. Med Electron Microsc. 2003;36:221–39.
34. Sbardella D, Inzitari R, Iavarone F, Gioia M, Marini S, Sciandra F, et al. Enzymatic processing by MMP-2 and MMP-9 of wild-type and mutated mouse beta-dystroglycan. IUBMB Life. 2012;64:988–94.
35. Zhong D, Saito F, Saito Y, Nakamura A, Shimizu T, Matsumura K. Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem Biophys Res Commun. 2006;345:867–71.
36. Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, et al. Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem. 2007;282:16036–41.
37. Court FA, Zambroni D, Pavoni E, Colombelli C, Baragli C, Figlia G, et al. MMP2-9 cleavage of dystroglycan alters the size and molecular composition of Schwann cell domains. J Neurosci. 2011;31:12208–17.
38. Shang ZJ, Ethunandan M, Gorecki DC, Brennan PA. Aberrant expression of beta-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in oral squamous cell carcinoma. Oral Oncol. 2008;44:1139–46.